600380 Joincare Pharmaceutical Group Industry
- 12.03
- +0.03+0.25%
Joincare Pharmaceutical Group Industry News
Health Yuan (600380.SH) announced first-quarter results, net profit of 440 million yuan, a year-on-year decrease of 4.96%
According to the Zhitong Finance App, Health Yuan (600380.SH) disclosed its report for the first quarter of 2024. During the reporting period, the company achieved revenue of 4.34 billion yuan, a year-on-year decrease of 4.81%; net profit to mother was 440 million yuan, a year-on-year decrease of 4.96%; after deducting non-net profit of 428 million yuan, a year-on-year decrease of 4.26%. Basic earnings per share were $0.2357.
Joincare Pharma Says Flu Drug Phase 3 Trial Attains Primary Endpoint
Joincare Pharmaceutical Group (SHA:600380) said its phase 3 trial for TG-1000 capsules as a treatment for influenza A and B reached the primary research endpoint, according to a Thursday filing with t
Health Source (600380.SH): TG-1000 capsule phase III clinical trial reached the main end
Gelonghui, April 17 | Health Source (600380.SH) announced that recently, the company's innovative drug product TG-1000 capsules for use in a multi-center phase III clinical trial (referred to as this study) with no complications in acute influenza A and B infections aged 12 and above (referred to as this study) reached the end of the main study. The company will communicate with the Drug Evaluation Center (CDE) of the China Drug Administration about the marketing application of TG-1000 capsules to treat influenza in the near future to advance the marketing process of TG-1000 capsules.
Some May Be Optimistic About Joincare Pharmaceutical Group IndustryLtd's (SHSE:600380) Earnings
The market for Joincare Pharmaceutical Group Industry Co.,Ltd.'s (SHSE:600380) shares didn't move much after it posted weak earnings recently. We did some digging, and we believe the earnings are str
Joincare Pharmaceutical Group IndustryLtd (SHSE:600380) Sheds 6.5% This Week, as Yearly Returns Fall More in Line With Earnings Growth
Generally speaking the aim of active stock picking is to find companies that provide returns that are superior to the market average. Buying under-rated businesses is one path to excess returns. To
Are Strong Financial Prospects The Force That Is Driving The Momentum In Joincare Pharmaceutical Group Industry Co.,Ltd.'s SHSE:600380) Stock?
Joincare Pharmaceutical Group IndustryLtd's (SHSE:600380) stock is up by a considerable 17% over the past month. Given that the market rewards strong financials in the long-term, we wonder if that i
Livzon Pharma to Trial JP-1366 Tablets as Reflux Esophagitis Drug
Livzon Pharmaceutical Group (HKG:1513, SHE:000513), a unit of Joincare Pharmaceutical (SHA:600380), will conduct clinical trials on JP-1366 tablets after obtaining the approval of China's National Med
Health Source (600380.SH): JP-1366 tablets obtained approval notice for drug clinical trials
On February 22, Ge Longhui Health Yuan (600380.SH) announced that the company's holding subsidiary, Livou Group Livzon Pharmaceutical Research Institute (hereinafter: Lizhu Research Institute), a wholly-owned subsidiary of the company, has received the “Drug Clinical Trial Approval Notice” (Notice Number: 2024LP00422) approved and issued by the State Drug Administration and approved JP-1366 tablets to conduct clinical trials. The first phase of JP-1366 was developed by Onconic Therapeutics Inc. (Onconic) in South Korea
Boan Biotechnology, Joincare Sign Exclusive License Deal for Respiratory Disease Treatment
Shandong Boan Biotechnology (HKG:6955) will grant Joincare Pharmaceutical Group Industry (SHA:600380) exclusive rights to develop, register, manufacture, and sell its BA2101 drug for chronic obstructi
Why Investors Shouldn't Be Surprised By Joincare Pharmaceutical Group Industry Co.,Ltd.'s (SHSE:600380) Low P/E
When close to half the companies in China have price-to-earnings ratios (or "P/E's") above 32x, you may consider Joincare Pharmaceutical Group Industry Co.,Ltd. (SHSE:600380) as a highly attractive in
Boan Biotech authorized Health Yuan to exclusively develop and commercialize BA2101's respiratory disease-related indications in mainland China
Yantai, January 26, 2024/PRNewswire/ -- Boan Biotech announced that it has reached a cooperation with Health Yuan Pharmaceutical Group Co., Ltd. (Health Yuan) on the exclusive right of anti-IL-4Rα long-term monoclonal antibody BA2101 injection to treat respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) in mainland China. According to the cooperation agreement, Health Yuan is authorized to exclusively develop, register, produce and commercialize BA2101 injections in mainland China for the treatment of respiratory diseases such as asthma and COPD. Boan Biotech continues to own this product in the field of respiratory diseases in mainland China
Boan Biotech (06955.HK) signed an exclusive licensing agreement with Health Yuan
Gelonghui, January 26, 丨 Boan Biotech (06955.HK) announced that the company has signed an agreement with Health Yuan Pharmaceutical Group Co., Ltd. The agreement relates to the exclusive authorized development and commercialization of the company's ongoing product BA2101 injection for the treatment of asthma and chronic obstructive pulmonary disease (COPD) and other respiratory diseases. According to the agreement, the company will grant Health Yuan exclusive rights to carry out the exclusive development, registration, production and commercialization of this product for indications in this field in mainland China. The company continues to hold the product in all other suitable areas outside of this field in the agreement area
Joincare Pharmaceutical, Guangzhou Fermion Technology Get Nod to Trial Analgesic Drug
Joincare Pharmaceutical Group (SHA:600380) said Guangzhou Fermion Technology recieved the approval of China's National Medical Products Administration to conduct clinical trials of the FZ008-145 capsu
Health Source (600380.SH): FZ008-145 capsules obtained clinical trial approval notice
On January 11, Gelonghui Health Yuan (600380.SH) announced that the company received a notice from Guangzhou Fermizi Technology Co., Ltd. (Fermizi), and Fermizi received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration to approve its self-developed FZ008-145 capsule (FZ008-145 for short) to carry out clinical trials. Previously, the Company and Fermizi have signed an agreement. Fermizi will exclusively grant the company the rights of the self-developed new analgesic drug FZ008-145 in Greater China, retaining the rights outside of Greater China. FZ008-1
Health Source (600380.SH): Compound ipratropium bromide solution for inhalation obtained drug registration approval in the Philippines
On January 9, Gelonghui Health Yuan (600380.SH) announced that the company received a drug registration certificate for compound ipratropium bromide solution for inhalation approved and issued by the Philippine Food and Drug Administration. The company's self-developed compound ipratropium bromide solution for inhalation (hereinafter referred to as this product) obtained the drug registration approval issued by the State Drug Administration in April 2019. This product is a combination of ipratropium bromide and salbutamol sulfate. It can act in combination with muscarine and beta-2-adrenaline receptors in the lungs to quickly relieve bronchospasm by relaxing smooth airway muscle and improving symptoms. Proof of clinical practice
Joincare Pharmaceutical Group IndustryLtd (SHSE:600380) Could Easily Take On More Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' When we think about how risky a company is, we always like
Livzon Pharmaceutical to Continue Getting Services From Joincare Pharmaceutical
Livzon Pharmaceutical Group (HKG:1513, SHE:000513) agreed to continue receiving a number of services from Joincare Pharmaceutical Industry Group (SHA:600380) for another year. Livzon will buy water, e
Health Source (600380.SH): TG-1000, a new class 1 influenza drug, has begun phase III clinical trials. Currently, the enrollment process is over half
Gelonghui, December 27丨Health Yuan (600380.SH) said on an interactive platform that the company's new class 1 influenza drug, TG-1000, has begun phase III clinical trials. Since autumn and winter are high influenza seasons, the enrollment process is now over half. We will proceed with clinical trials and subsequent marketing as soon as possible. If there is any relevant progress, the company will promptly fulfill its information disclosure obligations in accordance with relevant regulations.
Health Source (600380.SH): Did not buy trust wealth management products
On December 27, Gelonghui | Health Yuan (600380.SH) said on an interactive platform that the company did not buy trust wealth management products.
Health Source (600380.SH): The diabetes indications of the holding subsidiary Livou Group Simeglutide have completed phase III clinical enrollment
Gelonghui, December 27丨Health Yuan (600380.SH) said on an interactive platform that the company's holding subsidiary Lizhu Group Simeglutide's diabetes indications have completed phase III clinical enrollment, and research and development is progressing smoothly. Since the weight loss indications of the original research drug of this variety have not yet been approved domestically, the country needs to be approved for this indication before clinical trials can be carried out. The company will actively follow up on related work in the future. If there is any relevant progress, the company will fulfill its information disclosure obligations in accordance with regulations.
Analysis
Price Target
No Data
